Literature DB >> 34524678

Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.

Antonino Catalano1, Gian Luca Vita2, Federica Bellone3, Maria Sframeli3,2, Maria Grazia Distefano3, Matteo La Rosa3, Agostino Gaudio4, Giuseppe Vita3,2, Nunziata Morabito3, Sonia Messina3,2.   

Abstract

PURPOSE: An increased fracture risk is commonly reported in Duchenne muscular dystrophy (DMD). Our aim was to investigate bone mineral density (BMD) and bone turnover, including sclerostin, and their association with markers of cardiac and respiratory performance in a cohort of DMD subjects.
METHODS: In this single center, cross sectional observational study, lumbar spine (LS) BMD Z-scores, C-terminal telopeptide of procollagen type I (CTX) and osteocalcin (BGP), as bone resorption and formation markers, respectively, and sclerostin were assessed. Left ventricular ejection fraction (LVEF) and forced vital capacity (FVC) were evaluated. Clinical prevalent fractures were also recorded.
RESULTS: Thirty-one patients [median age = 14 (12-21.5) years] were studied. Ambulant subjects had higher LS BMD Z-scores compared with non-ambulant ones and subjects with prevalent clinical fractures [n = 9 (29%)] showed lower LS BMD Z-scores compared with subjects without fractures. LS BMD Z-scores were positively correlated with FVC (r = 0.50; p = 0.01), but not with glucocorticoid use, and FVC was positively associated with BGP (r = 0.55; p = 0.02). In non-ambulant subjects, LS BMD Z-scores were associated with BMI (r = 0.54; p = 0.02) and sclerostin was associated with age (r = 0.44; p = 0.05). Age, BMI, FVC and sclerostin were independently associated with LS BMD Z-score in a stepwise multiple regression analysis. Older age, lower BMI, FVC and sclerostin were associated with lower LS BMD Z-scores.
CONCLUSION: In a cohort of DMD patients, our data confirm low LS BMD Z-scores, mainly in non-ambulant subjects and irrespective of the glucocorticoid use, and suggest that FVC and sclerostin are independently associated with LS BMD Z-scores.
© 2021. Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Bone mineral density; Bone turnover; Duchenne muscular dystrophy; Forced vital capacity; Fractures; Glucocorticoid; Left ventricular ejection fraction; Sclerostin

Mesh:

Substances:

Year:  2021        PMID: 34524678     DOI: 10.1007/s40618-021-01676-4

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  59 in total

1.  Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.

Authors:  Shuko Joseph; Cunyi Wang; Kate Bushby; Michaela Guglieri; Iain Horrocks; Volker Straub; S Faisal Ahmed; Sze Choong Wong
Journal:  JAMA Neurol       Date:  2019-06-01       Impact factor: 18.302

2.  Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.

Authors:  A L Mayo; B C Craven; L C McAdam; W D Biggar
Journal:  Neuromuscul Disord       Date:  2012-07-21       Impact factor: 4.296

3.  The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.

Authors:  J Ma; H J McMillan; G Karagüzel; C Goodin; J Wasson; M A Matzinger; P DesClouds; D Cram; M Page; V N Konji; B Lentle; L M Ward
Journal:  Osteoporos Int       Date:  2016-10-24       Impact factor: 4.507

4.  Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy.

Authors:  S Akhtar Ali; H Kang; R Olney; L Ramos-Platt; A Ryabets-Lienhard; C Cheung; S Georgia; P Pitukcheewanont
Journal:  Osteoporos Int       Date:  2019-08-07       Impact factor: 4.507

Review 5.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

Review 6.  Muscular dystrophies: genes to pathogenesis.

Authors:  Isin Dalkilic; Louis M Kunkel
Journal:  Curr Opin Genet Dev       Date:  2003-06       Impact factor: 5.578

Review 7.  Corticosteroids for the treatment of Duchenne muscular dystrophy.

Authors:  Emma Matthews; Ruth Brassington; Thierry Kuntzer; Fatima Jichi; Adnan Y Manzur
Journal:  Cochrane Database Syst Rev       Date:  2016-05-05

Review 8.  Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.

Authors:  Antoine Boulanger Piette; Dounia Hamoudi; Laetitia Marcadet; Françoise Morin; Anteneh Argaw; Leanne Ward; Jérôme Frenette
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

9.  Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.

Authors:  Anna Rufo; Andrea Del Fattore; Mattia Capulli; Francesco Carvello; Loredana De Pasquale; Serge Ferrari; Dominique Pierroz; Lucia Morandi; Michele De Simone; Nadia Rucci; Enrico Bertini; Maria Luisa Bianchi; Fabrizio De Benedetti; Anna Teti
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

Review 10.  Optimizing Bone Health in Duchenne Muscular Dystrophy.

Authors:  Jason L Buckner; Sasigarn A Bowden; John D Mahan
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

View more
  3 in total

1.  Bone quality in Duchenne muscular dystrophy.

Authors:  J Finsterer; W Strobl
Journal:  J Endocrinol Invest       Date:  2022-03-10       Impact factor: 5.467

2.  Bone quality in Duchenne muscular dystrophy.

Authors:  A Catalano; G L Vita; S Messina
Journal:  J Endocrinol Invest       Date:  2022-03-11       Impact factor: 5.467

3.  Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.

Authors:  K Tsaknakis; K Jäckle; K A Lüders; H M Lorenz; L Braunschweig; A K Hell
Journal:  Osteoporos Int       Date:  2022-05-18       Impact factor: 5.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.